Senvest Management LLC Acquires Shares of 90,000 Pfizer Inc. (NYSE:PFE)

Senvest Management LLC purchased a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 90,000 shares of the biopharmaceutical company's stock, valued at approximately $2,388,000.

A number of other institutional investors also recently made changes to their positions in PFE. Passumpsic Savings Bank increased its stake in shares of Pfizer by 8.4% during the third quarter. Passumpsic Savings Bank now owns 25,680 shares of the biopharmaceutical company's stock valued at $743,000 after buying an additional 1,998 shares during the period. Virtu Financial LLC bought a new stake in shares of Pfizer during the 3rd quarter valued at about $1,499,000. Westside Investment Management Inc. increased its position in shares of Pfizer by 7.7% during the third quarter. Westside Investment Management Inc. now owns 14,008 shares of the biopharmaceutical company's stock valued at $404,000 after buying an additional 1,004 shares during the period. Diamant Asset Management Inc. lifted its holdings in Pfizer by 8.4% in the third quarter. Diamant Asset Management Inc. now owns 8,515 shares of the biopharmaceutical company's stock worth $246,000 after buying an additional 660 shares during the period. Finally, Morse Asset Management Inc bought a new stake in Pfizer during the 3rd quarter valued at approximately $2,649,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction dated Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares of the company's stock, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.06% of the company's stock.

Pfizer Stock Performance

NYSE:PFE traded up $0.09 during mid-day trading on Friday, hitting $22.13. 53,854,504 shares of the company traded hands, compared to its average volume of 40,458,828. The stock's fifty day moving average price is $24.95 and its 200-day moving average price is $26.23. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The firm has a market cap of $125.50 billion, a price-to-earnings ratio of 15.69, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm's quarterly revenue was up 24.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.10 EPS. Research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently weighed in on PFE. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. UBS Group dropped their price objective on shares of Pfizer from $28.00 to $24.00 and set a "neutral" rating on the stock in a research note on Tuesday, April 8th. Guggenheim restated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Finally, The Goldman Sachs Group reiterated a "neutral" rating and issued a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, Pfizer currently has a consensus rating of "Moderate Buy" and an average price target of $31.07.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.